Patients Discontinuing Slimming Injections Regain Weight Four Times Faster Than Those on Conventional Diets

New research suggests that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end traditional lifestyle regimens.

Research printed in a prominent health publication demonstrates that while obese individuals can lose about a fifth of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month after stopping.

"People purchasing these medications need to be informed of the potential of quick weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.

Such speed of regain suggests a reversion to pre-treatment weight within about one and a half years.

Weighing Approaches

The study, which looked at 37 of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with conventional dieting.

The team emphasize that individuals who shed pounds through diet and exercise usually have a slower creep back—perhaps 0.1 kg a month—once they finish.

Explaining the Rapid Regain

Doctors believe the way of the drugs is key to understanding the amplified regain.

These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate appetite.

"Artificially providing GLP-1 concentrations several times higher than normal might result in the system to produce less of its endogenous GLP-1, and could reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.

"Withdrawal of this medication means hunger is uncontrolled, making excessive eating a significant risk."

A Lifelong Disease?

Medical guidelines advise the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.

Professionals say that, due to the high risk of weight regain, the treatment is often long-term.

This opinion is echoed by pharmaceutical companies, who say that the results "underscore the persistent character of obesity," similar to managing conditions like high blood pressure.

Patient Experiences

Individuals who have discontinued the medication report a sudden return of hunger.

"It was like a trigger that goes on and you become ravenous," said an individual.

This difficulty is exacerbated if users have not developed lasting lifestyle or habit changes during treatment.

Widespread Use

Survey data show that a significant number of people in the UK have used these injections in the last 12 months, with demand being substantial.

• Adoption is more common among women compared to men.
• The middle-aged age group shows the greatest usage rates.
• Many access the medications through private prescriptions rather than the NHS.

Finally, clinicians emphasize that while these medications are potent agents for shedding pounds, they are not a standalone cure and long-term success likely depends on ongoing behavioural management.